A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of CHR-3996, a class 1 selective histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors.

2552 Background: CHR-3996, a class 1 selective HDACi inhibiting HDAC 1, 2, and 3 at low nanomolar concentrations, demonstrated antitumor activity in several xenograft tumor models. Objectives of th...